Lung highlights from ESMO 2018

Erlotinib for neoadjuvant treatment of EGFR NSCLC

IMpower132: atezolizumab, carboplatin and pemetrexed as first line treatment in key subgroups with stage IV non-squamous NSCLC

AURA 3: Mechanisms of osimertinib resistance in patients with EGFR T790M advanced NSCLC

Comment on the TRIBE-2 study on first and second-line treatment for metastatic colorectal cancer

Ceritinib and ribociclib in ALK-positive NSCLC

Cemiplimab in patients with hepatocellular carcinoma

Updates from the EMBRACA trial for advanced breast cancer

DPYD genotype-guided dose individualisation of fluoropyrimidine therapy

Therapeutic targeting at a pre-metastatic stage for brain metastases from lung cancer

Neoadjuvant ipilimumab plus nivolumab in early stage colon cancer

KEYNOTE022: Triplet therapy for BRAF melanoma